Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 05/09

20090137778 - Replikin peptides and antibodies therefore: The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease.... Agent: Kenyon & Kenyon LLP

20090137779 - Peptide inhibitors of thrombin as potent anticoagulants: The tetrapeptide Phe-Asn-Pro-Arg (SEQ ID NO: 3) is a structurally-optimized sequence for binding to the active site of thrombin. By conjugating this tetrapeptide or variants thereof to a C-terminal fragment of hirudin, we were able to generate a series of new multivalent inhibitors of thrombin containing only genetically encodable natural... Agent: Ogilvy Renault LLP

20090137780 - Method for production of peptide thioester compound: The present invention provides a process for producing a peptide thioester compound, characterized by comprising: (A) forming a peptide by a solid-phase synthesis method using a resin modified with a linker represented by the formula (1) as a solid phase; (B) cleaving a bond between the solid phase and the... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20090137781 - Method and device for producing a thread from silk proteins: The present invention relates to a thread preparation process from silk proteins including an apparatus which is appropriate for performing the method. Furthermore, the invention is directed to the threads obtained therewith as well as the use thereof. The invention uses a diffusion unit leading to the production of high-quality... Agent: The Nath Law Group

20090137783 - Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic... Agent: Philip S. Johnson Johnson & Johnson

20090137782 - Specific binding proteins and uses thereof: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of... Agent: Klauber & Jackson

20090137784 - Epidermal growth factor receptor polypeptides and antibodies: Antibodies and polypeptides that bind to and/or modulate the activity of receptors in the epidermal growth factor family are provided herein.... Agent: Fish & Richardson PC

20090137785 - Rab9 protein crystal structures and methods for identifying rab9 modulators: The present invention relates to crystalline Rab9 in complex with either GDP or the GTP analog Guanosine 5′-(β,γ-imido) triphosphate (GppNHp), the three dimensional coordinates and structures of Rab9 in Rab9-GDP and Rab9-GppNHp complexes, and uses thereof for drug design. In particular, the present invention relates to methods for producing Rab9... Agent: Alston & Bird LLP

20090137786 - Method for producing reduced keratin, reduced cuticle protein and mixture thereof: A method for producing a reduced keratin solution, a powder of reduced keratin, a reduced cuticle protein dispersion, an aqueous medium dispersion containing reduced keratin and reduced cuticle protein, or a mixed powder of reduced keratin and reduced cuticle protein, comprising the extraction step of dipping and heating a keratin-containing... Agent: Birch Stewart Kolasch & Birch

20090131634 - Method for preparing cell fraction containing hemangioblasts: Mouse PCLP1 was identified by expression cloning with the use of a monoclonal antibody against a surface antigen of a cell line derived from mouse AGM. By fractionating PCLP1-positive/CD45-negative cells and culturing them in vitro, it was clarified that these cells differentiate into endothelial-like cells, angioblast-like cells, and hematopoietic cells.... Agent: Wilmerhale/boston

20090131635 - Method for synthesizing polymer on substrate: For synthesizing a polymer, a substrate is placed within a reaction chamber, and a polymer synthesis sample is fed into the reaction chamber for forming the polymer on the substrate. In addition, the reaction chamber is shaken during formation of the polymer on the substrate within the reaction chamber for... Agent: Law Office Of Monica H Choi

20090131636 - Targeting vector-phospholipid conjugates: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in... Agent: Kramer Levin Naftalis & Frankel LLP

20090131637 - Vanilloid receptor: The isolated nucleic acid encoding human vanilloid receptor, said receptor, it's preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in humans. The receptor is involved in detection of noxious stimuli in mammalian organisms.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090131638 - Anti-myostatin antibodies: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in... Agent: Eli Lilly & Company

20090131639 - Antibody-containing solution formulations: Antibody-containing solution formulations including a sugar as a stabilizer. Said solution formulations can further include a surfactant as a stabilizer.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090131640 - Photoluminescent metal complexes for protein staining: A method of staining a poly(amino acid) by contacting a poly(amino acid) with a complex of at least one of transition metal ion, and a plurality of donor ligands each of which is fully coordinated to the transition metal ion and is either a nitrogen donor ligand or a cyclometalated... Agent: Townsend And Townsend And Crew, LLP

20090131641 - Method for assembling subunits into capsoids: The invention relates to a method for assembling subunits forming capsoides in a solution containing a reduction agent in order to obtain capsoides. Initially, the reduction agent is inactivated or removed from the solution, subsequently, the ionic strength in the solution is increased to such an extent by adding at... Agent: Kanesaka Berner And Partners LLP

20090124790 - Chromatographic method and system for purifying a botulinum toxin: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.... Agent: Allergan, Inc.

20090124791 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090124792 - Fluorescent polymethine cyanine dyes: The invention encompasses fluorescent cyanine dyes and methods of using such dyes. In particular, the invention encompasses near infrared polymethine cyanine dyes.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090118467 - Macromolecular compounds having controlled stoichiometry: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at... Agent: Knobbe Martens Olson & Bear LLP

20090118468 - Cynomolgus prostate specific antigen: Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090118469 - High-affinity antagonists of elr-cxc chemokines: The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists.... Agent: Ade & Company Inc.

20090118471 - Novel coumarin derivatives: A compound represented by the following general formula (I) or a salt thereof [R1 represents hydrogen atom, or a C1-12 alkyl group; R2 represents a C1-12 alkyl group having one or more maleimide groups, an aryl group having two or more maleimide groups, a group represented by the formula (A):... Agent: Greenblum & Bernstein, P.L.C

20090118470 - Prion inactivation: Subject of the invention is a process for the inactivation of prions in a sample which comprises prion proteins or is suspected of comprising prion proteins, the process comprising a heat treatment in the presence of a lipophilic substance comprising at least 8 carbon atoms, wherein the heat treatment is... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090118472 - Biomarkers for toxic algae: The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can... Agent: Evan Law Group LLC

20090118473 - Mn gene and protein: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the... Agent: Leona L. Lauder

20090118474 - Method and composition for crystallizing g protein-coupled receptors: Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090118475 - Clostridial neurotoxin compositions and modified clostridial neurotoxins: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In... Agent: Allergan, Inc.

20090118476 - Purification of pegylated polypeptides: The invention is a method for the purification of mono-PEGylated erythropoietin using two cation exchange chromatography steps wherein the same type of cation exchange material is used in both cation exchange chromatography steps and a method for producing a mono-PEGylated erythropoietin in substantially homogeneous form.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090118477 - Continuous counter-current organosolv processing of lignocellulosic feedstocks: A modular process for organosolv fractionation of lignocellulosic feedstocks into component parts and further processing of said component parts into one or more of a de-lignified cellulose stream, a sugar stream, small-chain alcohol streams and four structurally distinct classes of lignin derivatives. The modular process comprises a first processing module... Agent: Fasken Martineau Dumoulin, LLP